Fenwick & West represented LifeSprout, a Johns Hopkins spinout bringing soft tissue replacement technology to market, in its $6.5 million financing. Medytox Investments, Kairos Ventures, Triskelion Capital and TEDCO led the round.
LifeSprout will use the funding to move forward with its initial product, which can be used for aesthetic enhancements to the face. The funding will help with the development of the product as LifeSprout seeks regulatory guidance and moves toward human trials. More information about LifeSprout’s $6.5 million financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate lawyers Ian Goldstein, Allison Cooper and Feihong Xu; and tax lawyer Ora Grinberg.